A chemical compound of formula (I) wherein R.sub.1 to R.sub.3 are independently selected from hydrogen and alkyl; R.sub.4 to R.sub.7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, monoalkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, arylthio, arylsulfoxyl, arylsulfonyl, alkylsulfoxyl, alkylsulfonyl, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino; and R.sub.8 is selected from alkyl and alkoxy, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity. ##STR1##

Un residuo del prodotto chimico della formula (i) in cui R.sub.1 a R.sub.3 sono scelti indipendentemente da idrogeno e da alchile; R.sub.4 a R.sub.7 sono scelti indipendentemente da idrogeno, da alogeno, da idrossilato, da alchilico, da arilico, da amminico, monoalkylamino, dialkylamino, alcossi, aryloxy, alkylthio, arylthio, arylsulfoxyl, arylsulfonyl, alkylsulfoxyl, alkylsulfonyl, nitro, ciano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, amminocarbonile, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino e dialkylaminocarbonylamino; e R.sub.8 è scelto e farmaceuticamente dai sali e dai prodrugs accettabili alchilici ed alcossi di ciò e dall'uso di ciò nella terapia, specialmente per il trattamento dei disordini del sistema nervoso centrale; danneggiamento del sistema nervoso centrale; disordini cardiovascolari; disordini gastrointestinali; insipidus del diabete ed apnea di sonno e specialmente per il trattamento di obesità. ## del ## STR1

 
Web www.patentalert.com

< Benzimidazolinyl piperidines as CGRP ligands

< Oxazolidinedione derivatives and their use

> Compositions containing hypoglycemically active stilbenoids

> Therapeutic agent comprising (+)-sibutramine

~ 00067